Sarepta Therapeutics (SRPT) Tops Q1 EPS by 217c

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of $3.16, $2.17 better than the analyst estimate of $0.99. Revenue for the quarter came in at $730.8 million versus the consensus estimate of $474.26 million.

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Gordon Haskett cuts TJX Companies rating to Accumulate
• Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
• Guggenheim Reiterates Neutral Rating on CrowdStrike (CRWD)